Roche Advances Experimental Eye Therapy as Regulators Review Application
Swiss pharmaceutical company Roche has reported encouraging one-year clinical results for vamikibart, an experimental medicine being developed for a sight-threatening eye condition associated with inflammation. Findings from two Phase III studies indicate that improvements in patients’ vision and reductions in retinal swelling were maintained through 52 weeks, strengthening the case for further regulatory review of…
